Imatinib Completed Phase 2 Trials for Prognostic Stage IV Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Positive / Cancer, Breast / one to five years postmenopausal / PDGFR Positive / KIT Positive / Progesterone Receptor Positive Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00338728Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
NCT00087152S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
NCT00193180Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer